Koers Sonoma Pharmaceuticals Inc Nasdaq
Aandelen
US83558L1052
Farmaceutische producten
Omzet 2024 * | 14,7 mln. 13,79 mln. | Omzet 2025 * | 17,9 mln. 16,79 mln. | Marktkapitalisatie | 2,5 mln. 2,34 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -5 mln. -4,69 mln. | Nettowinst (verlies) 2025 * | -3 mln. -2,81 mln. | EV/omzet 2024 * | 0,17 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 0,14 x |
K/w-verhouding 2024 * |
-0,18
x | K/w-verhouding 2025 * |
-0,36
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,44% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Amy Trombly
CEO | Chief Executive Officer | 57 | 27-09-19 |
John Poggetto
DFI | Director of Finance/CFO | 53 | 01-01-02 |
Jerome Dvonch
DFI | Director of Finance/CFO | 56 | 08-09-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Amy Trombly
CEO | Chief Executive Officer | 57 | 27-09-19 |
Jay Birnbaum
BRD | Director/Board Member | 79 | 20-04-07 |
Director/Board Member | 64 | 19-09-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+34,00% | 664 mld. | |
+29,29% | 567 mld. | |
-7,75% | 354 mld. | |
+18,53% | 330 mld. | |
+4,95% | 286 mld. | |
+13,79% | 234 mld. | |
+4,93% | 199 mld. | |
-9,78% | 196 mld. | |
-4,89% | 148 mld. |